Quick Takeaways
- This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 05 Aug 2024, 16:21.
PATRICK DEVAL L - 01 Aug 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Role
- Director
- Signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
- Issuer symbol
- N/A
- Transactions as of
- 01 Aug 2024
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 05 Aug 2024, 16:21:01 UTC
- Previous filing
- 10 Jun 2024
- Next filing
- 17 Sep 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 05 Aug 2024."
What Changed
- Previous filing in this sequence was filed on 10 Jun 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERE | Common Stock | Disposed to Issuer | -3,282 | -24% | 10,461 | 01 Aug 2024 | Direct | F1 | ||
| transaction | CERE | Common Stock | Disposed to Issuer | -10,461 | -100% | 0 | 01 Aug 2024 | Direct | F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERE | Stock Option (Right to Buy) | Disposed to Issuer | -49,794 | -100% | 0 | 01 Aug 2024 | Common Stock | 49,794 | Direct | F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
PATRICK DEVAL L is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| F2 | These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| F3 | At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |